US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

647.43

+10.931.72%

Number of Gainers:3

Number of Losers:1

Number of Flat:- -

PE:- -

High:656.03

Open:636.50

Low:633.69

Close:636.50

Volume:18.40M

Turnover:425.18M

Market Cap:20.10B

Float Cap:14.69B

Loading ...

CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary

Switzerland's CRISPR Therapeutics Q1 net loss narrows

CRISPR Therapeutics Q1 net loss narrows to $122.9 million; revenue hits $43 million

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Recursion Pharmaceuticals Inc expected to post a loss of 27 cents a share - Earnings Preview

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simply Wall St.

Recursion Pharmaceuticals Is Maintained at Overweight by JP Morgan

Recursion Pharmaceuticals Announces Planned Board Leadership Transition

Recursion founder Chris Gibson to step down from board in June

Recursion Pharmaceuticals announces annual shareholder meeting

Tempus AI CEO Eric Lefkofsky disposes of shares worth $8.54 million

Recursion Announces Board Transition

Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan

Tempus AI to host inaugural investor day, webcast available

Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes

Recursion updates financial calendar with upcoming first-quarter results and earnings call

Press Release: Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Intellia Therapeutics Reports Positive Phase 3 Trial Results for CRISPR-Based Gene Therapy

Can Tempus AI’s (TEM) USC Partnership Quietly Redefine Its Clinical Data Moat?

Simply Wall St.

Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":647.42786,"timestamp":1777924799999,"preClose":636.4972,"halted":0,"volume":18400263,"delay":0,"changeRate":0.017173,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":10.930664,"latestTime":"05-04 16:00:00 EDT","open":636.4972,"high":656.02985,"low":633.6882,"amount":425183668.221941,"amplitude":0.035101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777939200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.150913,"peRate":-12.795828,"turnoverRate":0.026393,"increases":3,"decrements":1,"flats":0,"marketCap":20102497024,"floatMarketCap":14691959040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":656.02985,"amplitude":0.035101,"preClose":636.4972,"low":633.6882,"pbRate":"4.150913","latestPrice":647.42786,"volume":18400263,"delay":0,"open":636.4972,"prevYearClose":658.3995,"prevWeekClose":636.4972,"prevMonthClose":641.0807,"prevQuarterClose":542.5347,"fiveDayClose":618.7574,"twentyDayClose":560.9409,"sixtyDayClose":580.8815,"secType":"PLATE","market":"US","turnoverRate":0.026393,"peRate":-12.795828,"marketCap":20102497024,"floatMarketCap":14691959040,"timestamp":1777924799999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":3,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633961520","title":"CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961520","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961520?lang=en_us&edition=fundamental","pubTime":"2026-05-05 05:09","pubTimestamp":1777928946,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG reports results for the quarter ended March 31 - Earnings SummaryCRISPR Therapeutics AG CRSP.OQ reported a quarterly adjusted loss of $1.28 per share for the quarter ended March","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H2DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU1861559042.SGD","BK4585","BK4556","CRSP","BK4139","BK4588","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699999","title":"Switzerland's CRISPR Therapeutics Q1 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633699999?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:43","pubTimestamp":1777927432,"startTime":"0","endTime":"0","summary":"Switzerland's CRISPR Therapeutics Q1 net loss narrowsOverviewSwitzerland-U.S. gene-editing biotech's Q1 revenue missed analyst expectationsQ1 EPS was -$1.28; net loss narrowed from prior yearOperating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL1N41H132:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4611","BK4556","BK4139","CRSP","LU1861559042.SGD","LU1861558580.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969311","title":"CRISPR Therapeutics Q1 net loss narrows to $122.9 million; revenue hits $43 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969311?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:39","pubTimestamp":1777927147,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics posted a net loss of USD 122.9 million for first-quarter 2026, narrowing from USD 136 million a year earlier, while CASGEVY revenue totaled USD 43 million.Cash, cash equivalents, and marketable securities climbed to USD 2.44 billion as of March 31, up from USD 1.98 billion at year-end 2025, driven primarily by USD 585.4 million of net proceeds from issuance of convertible senior notes in March.R&D expenses fell to USD 68.6 million from USD 72.5 million, while G&A expenses eased to USD 17.2 million from USD 19.3 million.Collaboration expense, net, declined to USD 45.9 million from USD 57.5 million, on an increase in its share of CASGEVY revenue.More than 500 people globally have initiated the CASGEVY treatment journey, while FDA cleared IND expansion for zugo-cel into autoimmune neurologic diseases and the company reiterated plans to start CTX340 in first-half 2026 and CTX460 in mid-2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbngPty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","SG9999014039.USD","IE00BN0W2W23.USD","LU1861558580.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014005.SGD","CRSP","IE00B64PRP62.GBP","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","SG9999014013.SGD","LU1861559042.SGD","BK4588","BK4556","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969366","title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969366?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, May  04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287176/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","CAT","BK4516","LU1861559042.SGD","CAR","LU1720051108.HKD","LU1861558580.USD","KSA","IE00BD6J9T35.USD","LU0942090050.USD","LU0251142724.SGD","LU2237438978.USD","LU0742534661.SGD","LU0251131958.USD","LU2264538146.SGD","SLE","LU0963586101.USD","LU1064131342.USD","LU2357305700.SGD","BK4597","BK4556","LU1720051017.SGD","BK4022","UAE","BK4149","BK4520","LU1917777945.USD","LU1974910355.USD","LU1988902786.USD","CRSP","IND","AGT","ITP","LU0868494708.USD","BK4077","FXI","BK4199","BK4611","BK4139","BK4230","BK4532","BK4585","LU2106854487.HKD","LU2543165471.USD","SCD","LU0048573561.USD","IE00BSNM7G36.USD","LU0868494617.USD","LU2023250504.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955424","title":"Recursion Pharmaceuticals Inc  expected to post a loss of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955424","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955424?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:09","pubTimestamp":1777900147,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc  expected to post a loss of27cents a share - Earnings Preview Recursion Pharmaceuticals Inc RXRX.OQ RXRX.O is expected to  show a rise in quarterly revenue when it report","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H196:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4548","RXRX","BK4139","BK4609","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632467486","title":"A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2632467486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632467486?lang=en_us&edition=fundamental","pubTime":"2026-05-03 01:43","pubTimestamp":1777743803,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) is back in focus after TIME named it among 2026’s 10 Most Influential Health & Life Science Companies, alongside encouraging Phase 1/2 BEACON data in sickle cell disease treatment.\nSee our latest analysis for Beam Therapeutics.\nInvestors appear to be responding to the TIME recognition and encouraging BEACON data, with the 7-day share price return of 13.24% and 30-day share price return of 26.75% pointing to strengthening momentum. The 1-year total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-time-recogn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/a-look-at-beam-therapeutics-beam-valuation-after-time-recogn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","PRGS","BK4556","LU1861558580.USD","BK4097","LU1861559042.SGD","BK4505","BK4535","BEAM","TIME","BK4588","BK4139","BK4611","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632602346","title":"Recursion Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632602346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632602346?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:52","pubTimestamp":1777589520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 18:52 ET (22:52 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","BK4539","BK4139","BK4548","LU0106831901.USD","LU1244550577.SGD","BK4534","LU1732800096.USD","LU1791710400.SGD","LU2133065610.SGD","LU2357305700.SGD","RXRX","LU0528227936.USD","LU2089283258.USD","LU0158827781.USD","LU0882574139.USD","BK4127","LU0971096721.USD","BK4504","LU1548497426.USD","LU2028103732.USD","LU0225283273.USD","LU0158827948.USD","LU1720051017.SGD","BK4581","LU0557290698.USD","LU0314104364.USD","LU1162221912.USD","LU0234570918.USD","LU0795875169.SGD","BK4588","LU2089284900.SGD","BK4609","LU1720051108.HKD","LU0106261372.USD","LU1244550221.USD","LU1791710582.SGD","LU2023251221.USD","LU1989772923.USD","LU0098860793.USD","LU0912757837.SGD","BK4611","LU0006306889.USD","LU1668664300.SGD","LU2271345857.HKD","LU2111349929.HKD","LU1074936037.SGD","BK4585","LU1244550494.USD","LU0320765646.SGD","LU2347655156.SGD","IE00BZ1G4Q59.USD","LU1732799900.SGD","LU0795875086.SGD","IE00BKVL7J92.USD","LU1989772840.SGD","LU0267386448.USD","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632606146","title":"Recursion Pharmaceuticals Announces Planned Board Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2632606146","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632606146?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:24","pubTimestamp":1777587879,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals ( ($RXRX) ) just unveiled an announcement. On April 28, 2026, Recursion Pharmaceuticals announced that founder and Chair ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-announces-planned-board-leadership-transition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-announces-planned-board-leadership-transition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RXRX","BK4611","BK4139","BK4609","BK4548","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664763","title":"Recursion founder Chris Gibson to step down from board in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664763","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664763?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:23","pubTimestamp":1777584207,"startTime":"0","endTime":"0","summary":"Recursion disclosed that founder Chris Gibson will finish his board term in June 2026 and will not seek re-election.Gibson will continue with company as a strategic advisor.Najat Khan is CEO and president; Rob Hershberg is vice-chair of board and lead independent director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL4WrKVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4609","BK4139","BK4611","BK4548","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632866416","title":"Recursion Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632866416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632866416?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:17","pubTimestamp":1777583823,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals schedules 2026 annual shareholder meeting for June 17, 2026 in virtual format.Shareholders will vote on election of two Class II directors, including Najat Khan and Franziska Michor.Meeting agenda includes advisory vote on named executive officer compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbWXMLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4611","RXRX","BK4539","BK4548","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632137661","title":"Tempus AI CEO Eric Lefkofsky disposes of shares worth $8.54 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632137661","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632137661?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:54","pubTimestamp":1777582493,"startTime":"0","endTime":"0","summary":"Tempus AI CEO and Chairman Eric P. Lefkofsky reported sales of 166,250 Class A common shares on April 28.Sales were executed at weighted average prices of $51.03 and $51.52.Holdings reported through Gray Media and Blue Media fell to 8,841,783 shares and 15,656,469 shares.Lefkofsky also reported 2,253,056 shares held directly following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL4R2tS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI CEO Eric Lefkofsky disposes of shares worth $8.54 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","TEMT","BK4121","LU1861558580.USD","BK4611","BK4125","BK4613","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669481","title":"Recursion Announces Board Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669481","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669481?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:30","pubTimestamp":1777581000,"startTime":"0","endTime":"0","summary":"Salt Lake City, UT, April  30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibso","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285514/0/en/Recursion-Announces-Board-Transition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","RXRX","BK4609","BK4611","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631651334","title":"Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2631651334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631651334?lang=en_us&edition=fundamental","pubTime":"2026-04-30 23:21","pubTimestamp":1777562479,"startTime":"0","endTime":"0","summary":"JPMorgan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $11 and keeps an Overweight rating on the shares. Publishe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-10-from-11-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-10-from-11-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034235303.USD","LU0868494617.USD","LU0048584097.USD","LU0417517546.SGD","LU1244550577.SGD","IE00BLSP4239.USD","LU1974910355.USD","LU2756315318.SGD","LU1116320737.USD","JPMO","LU2430703178.SGD","LU1988902786.USD","IE00BJTD4N35.SGD","LU0211327993.USD","LU0820562030.AUD","LU2236285917.USD","LU2237443895.HKD","LU0203345920.USD","LU1496350171.SGD","LU0942090050.USD","BK4207","IE0034235188.USD","LU2756315664.SGD","LU1496350502.SGD","IE00BLSP4452.SGD","LU0265550946.USD","BK4516","LU0211331839.USD","LU1119994496.HKD","LU0238689110.USD","LU2357305700.SGD","LU2264538146.SGD","IE00B775SV38.USD","LU2054465674.USD","BK4581","IE00BHPRN162.USD","BK4566","LU2381873111.SGD","LU0820561818.USD","LU0868494708.USD","LU2237443978.SGD","IE00BJLML261.HKD","LU0256863811.USD","LU2430703095.HKD","LU1064131342.USD","LU0215105999.USD","LU0859254822.USD","IE00BDRTCR15.USD","LU0689472784.USD","LU2106854487.HKD","LU2552382215.SGD","LU1917777945.USD","LU0251132253.USD","IE00BZ1G4Q59.USD","LU2242649171.HKD","LU0106831901.USD","LU1363072403.SGD","LU0070302665.USD","LU0976567544.SGD","LU2746668974.SGD","IE00B3S45H60.SGD","LU0345769631.USD","LU0323591593.USD","LU2417539215.USD","LU2237443382.USD","IE00BDCRKT87.USD","IE00B1XK9C88.USD","LU0208291251.USD","LU0882574139.USD","LU2237443622.USD","BK4504","LU0345770993.USD","LU1084165304.USD","LU0267386448.USD","LU1145028129.USD","LU1894683348.USD","LU2552382132.HKD","IE00BBT3K403.USD","SG9999002232.USD","LU2237443549.SGD","LU2430703251.USD","LU2505996681.GBP","BK4611","BK4534","LU2456880835.USD","BK4609","LU0006306889.USD","LU1366192091.USD","LU0310799852.SGD","LU0234572021.USD","LU0971096721.USD","LU1668664300.SGD","LU1720051108.HKD","LU1548497426.USD","LU0106261372.USD","LU2552382058.USD","SG9999002224.SGD","LU0265550359.USD","LU0320765489.SGD","LU0203347892.USD","LU0820561909.HKD","IE00BJTD4V19.USD","RXRX","BK4550","IE00BKDWB100.SGD","BK4139","LU1551013342.USD","LU2211815571.USD","BK4588","BK4539","LU0640476718.USD","LU1162221912.USD","LU2746668461.USD","LU0211326755.USD","LU1244550494.USD","LU0496365809.HKD","LU0943347566.SGD","LU1670627923.USD","JPO","IE0034235295.USD","LU0256863902.USD","LU2023250504.SGD","IE00B1BXHZ80.USD","LU0211326839.USD","LU1894683264.USD","LU1244550221.USD","LU2023250330.USD","LU2505996509.AUD","LU2237443465.HKD","IE00BFXG1179.USD","LU2592432038.USD","BK4585","LU0170899867.USD","LU1629891620.HKD","LU1670628061.USD","LU1267930490.SGD","LU1914381329.SGD","IE00BKVL7J92.USD","LU2462157665.USD","LU1261432733.SGD","LU2213496289.HKD","LU1551013425.SGD","LU0211328371.USD","JPM","LU1116320901.HKD","LU0787776722.HKD","LU0149725797.USD","IE00BYXW3230.USD","LU2357627491.SGD","BK4548","LU2023250843.SGD","LU0683600562.USD","IE00BWXC8680.SGD","LU0320765646.SGD","LU0345769128.USD","LU1280957306.USD","IE00BN8TJ469.HKD","LU1720051017.SGD","LU1032466523.USD","LU0345770308.USD","BK4533","IE000M9KFDE8.USD","LU0964807845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631511987","title":"Tempus AI to host inaugural investor day, webcast available","url":"https://stock-news.laohu8.com/highlight/detail?id=2631511987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631511987?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:32","pubTimestamp":1777465941,"startTime":"0","endTime":"0","summary":"Tempus AI will host an Investor Day on May 29, 2026.Event is scheduled to start at 8:00 a.m. CT.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL7Wz1MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","BK4611","BK4121","LU1861558580.USD","LU1861559042.SGD","TEMT","BK4613"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2631516171","title":"Press Release: Morningstar Reaches New Milestone in the CRSP Acquisition, Rebranding CRSP Market Indexes to Morningstar Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516171","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516171?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464000,"startTime":"0","endTime":"0","summary":"The rebrand of the CRSP indexes, with over $3 trillion in AUM benchmarked, solidifies Morningstar's position as one of the top tier index providers and is an important new milestone in the CRSP integration.Morningstar, Inc. , a leading provider of independent investment insights, has reached a new milestone in its previously completed acquisition of the Center for Research in Security Prices  from the University of Chicago, announcing the rebrand of the CRSP Market Indexes to reflect the Morningstar brand.Added Amelia Furr, president of Morningstar Indexes, \"Now with over $4.2 trillion in assets linked to our benchmarks, including over 370 investment products, Morningstar offers an expansive alternative to legacy index providers. Adding the Morningstar brand to the CRSP indexes is another step in growing global visibility for this high-quality methodology. We are committed to scaling our U.S. index capabilities and extending our reach to more clients across the market and investing eco","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","LU1878469433.USD","BK4556","LU1861558580.USD","BK4588","BK4611","BK4585","BK4112","BK4598","LU1861559042.SGD","MORN","BK4139","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516923","title":"Recursion updates financial calendar with upcoming first-quarter results and earnings call","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516923","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516923?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:59","pubTimestamp":1777463960,"startTime":"0","endTime":"0","summary":"Recursion will report first-quarter 2026 financial results on May 6, 2026, before US market open.Earnings call scheduled for May 6, 2026 at 8:00 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4GvcxN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4609","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","RXRX","BK4539","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","BK4548","BK4139","BK4611","IE00BN0W2T93.GBP","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631169045","title":"Press Release: Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2631169045","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631169045?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:59","pubTimestamp":1777463940,"startTime":"0","endTime":"0","summary":"Salt Lake City, UT, April 29, 2026  -- Recursion , a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets.This document contains information that includes or is based upon \"forward-looking statements\" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4609","BK4611","BK4539","RXRX","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114056120","title":"Intellia Therapeutics Reports Positive Phase 3 Trial Results for CRISPR-Based Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1114056120","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114056120?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:11","pubTimestamp":1777291870,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics has announced that its CRISPR gene-editing therapy for a rare swelling disorder has successfully met all primary endpoints in a pivotal late-stage clinical trial. This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4588","CRSP","BK4585","LU1861559042.SGD","BK4139","LU1861558580.USD","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630869373","title":"Can Tempus AI’s (TEM) USC Partnership Quietly Redefine Its Clinical Data Moat?","url":"https://stock-news.laohu8.com/highlight/detail?id=2630869373","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630869373?lang=en_us&edition=fundamental","pubTime":"2026-04-26 13:08","pubTimestamp":1777180083,"startTime":"0","endTime":"0","summary":"In April 2026, Tempus AI, Inc., the Keck School of Medicine of USC, and Keck Medicine of USC announced a multi-faceted collaboration to embed Tempus’ AI-enabled molecular diagnostics, clinical trial matching, and care-gap analytics across more than 1.5 million annual patient visits in USC-affiliated hospitals and clinics.\nThis partnership is distinctive because it couples Tempus’ data and AI infrastructure with a major academic health system’s real-world patient volume, creating a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/can-tempus-ais-tem-usc-partnership-quietly-redefine-its-clin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/can-tempus-ais-tem-usc-partnership-quietly-redefine-its-clin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861558580.USD","BK4588","BK4585","BK4587","LU1861559042.SGD","BK4613","BK4611","TEMT","BK7095","BK4023","BK4543","AIYY","BK4121","BK4528","BK4551","VGT","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629562842","title":"Is CRISPR Therapeutics (CRSP) Share Price Aligning With Its Long Term Growth Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629562842","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629562842?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:13","pubTimestamp":1777036417,"startTime":"0","endTime":"0","summary":"Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you.\nThe stock has seen a 41.1% return over the last year, with a 30 day return of 18.8%, while also showing shorter term volatility such as a 1% decline over the last week and a 5 year return of negative 58.2%.\nRecent headlines around CRISPR Therapeutics continue to keep attention on the company,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-share-price-aligning-with-its-lo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4556","CRSP","LU1861559042.SGD","BK4611","DCF","BK4139","BK4588","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}